SynInnova is a fully integrated chemistry service provider established to lessen the burden of drug development costs of pharmaceutical and biotech industries. We offer Ph.D. and M.S. level Full Time Equivalent (FTE) scientists who have extensive experience in broad spectrum of chemical synthesis. We gain our customers' trust through our perseverance and strong commitment to quality, confidentiality and time lines.

In general, contract research can be conducted to develop synthesis of novel compounds, reagents or a new synthetic strategies. At SynInnova we continually do research to provide new synthetic methodologies, optimization of existing synthetic pathways and development of specialty reagents to maintain a competitive edge and improve cost efficiency for us and our customers.

We will conduct literature studies and conduct preliminary studies to determine feasibility of pertinent synthetic methods. If we mutually agree to pursue the project, a research agreement must be signed. One or more full-time chemists will be assigned to the project. Progress of the work is communicated at regular intervals, in written weekly or monthly reports. Samples of intermediate compounds are available on request at any stage of the synthesis. Final products will be shipped as per the customers' request and transfer all the documentation to customers under strict confidentiality.

Cost effective procedures are playing major role in R & D of the current drug development in spite of the growing demand for novel drugs in the market. Therefore there is an increasing demand for custom synthesis and that is why we are in the business. We take your pressures and create your dream products at the price you can afford. Our highly qualified scientific staff can handle any kind of projects prudently within the committed timelines. With the track record of over 97% success rate, we assure you that you get charged only once we deliver products up to your satisfaction.

Our frequent custom synthesis requests are: ready to use building blocks, tag molecules, intermediates, small molecules, reference compounds and novel reagents. Our highly qualified team has wide knowledge and experience of a variety of chemistry areas and has capabilities of synthesizing any challenging molecule in cost effective manner. Our expertise in aliphatic, aromatic, heterocyclic, boronic acid/ester, carbohydrate, and peptide synthesis help you to make your desired products in the required quantities.

• Provide diverse early and advanced chemical building blocks to speed up discovery in all disciplines of research and therapeutic areas
• Custom synthesis of FDA approved drugs as reference compounds.
• Custom synthesis of drugs under clinical trials as reference compounds.
• Custom synthesis of drug metabolites, impurities.
• Custom synthesis of your proprietary designed molecules in a specific drug discovery project under confidential agreement.
• Fine Chemicals.
• Specialty chemicals as per customer's request.
• Stable isotopic labelled products.
• Custom synthesis of versatile drug like scaffolds and molecules.
• Chiral intermediates and final products with high enantiomeric access.
• In partnership with SynInnova we could assist you in designing and synthesizing additional analogs of your specific proprietary scaffold with the help of our in-house medicinal chemist.
• Robust building blocks (amines, amides, aldehydes, ketones, halides, esters, acids, alcohols, monocyclic and bicyclic aromatic and heteroaromatic scaffolds, boronic acids, steroids and carbohydrates).
• Pharmaceutical API and Bulk Intermediates through overseas contacts.

Over 80% of drug candidates are mostly chiral substances, such as amino acids, carbohydrates, proteins, and nucleic acids. Since the different enantiomers of chiral substances have different physiological activities to the biological targets, it is very important to separate and synthesize pure single enantiomers. A single-configuration chiral molecule is usually a stereoisomer with desired biological activity, but its mirror image molecule is useless or even harmful. Thus it is necessary to obtain a single chiral enantiomer. By employing state-of-the-art numerous technologies including crystallization resolution, enzymatic resolution, chemical resolution, asymmetric synthesis, HPLC, SFC (supercritical fluid chromatography), as well as a dedicated team of experts SynInnova would be able to provide chiral analysis and separation services in this increasingly complex and high demand area of research.

Peptide therapeutics demonstrated commercial success since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are approved in the United States and other major markets, and peptides continue to enter clinical development at a steady pace. Not surprisingly, the areas of highest concentration for peptide development are areas of high interest to the pharmaceutical industry: metabolic disease, oncology, and cardiovascular disease. Research continues to expand the potential range of peptide-based pharmaceuticals to new targets. Over 150 peptides are in active development today. With a dedicated team of experts, SynInnova would be glad to support your peptide-based research.

SynInnova has further expanded its capabilities to include production of stable isotope labelled compounds (SILC). We have an experienced team of scientists to produce stable isotopic labelled compounds in Life Science applications, including biomedical investigations for the development of new drugs. We are excited to offer these SILC products with high quality standards expected in the industry (>98% isotopic and chemical purity) and with competitive prices.

At SynInnova we are working on a wide verity of biologically active compounds, analytical reference standards, drug impurities, metabolites of D, 13C, 15N, and/or 18O. If you cannot find the SILC that you are looking for, then we are happy to provide you a free quote. If you are unsure of the best compound for your research or you want to design a compound with the best cost then we can help with that too. Our experience with stable isotope production and with other custom synthesis projects ensures that we can work with you to successfully design and produce a compound to accelerate your Life Science research.

If you need any specific labelled compound(s), please feel free to contact us at sales@syninnova.com.

As the industry is driving towards the cost effectiveness, it is very important to incorporate the best drug characteristics at the earliest possible stage which is achieved by lead optimization. In spite of advanced computer modelling programs, the limiting factor is still the generation of high quality compound libraries. At SynInnova our experienced team of medicinal chemists develop strategies tailored to clients needs taking ADME and toxicity issues into consideration to maximize results and minimize the time lines.

We offer the medicinal chemistry services at SynInnova to our customers to design and synthesis of novel compounds against a number of diseases of our customer's interest.

We provide the following services starting from a validated lead compound usually provided by the customer:

• Systematic SAR study
• Design of new analogues directed towards optimization of potency, selectivity and improvement of the ADME-Tox profile
• Consolidation of the IP position
• Analogue resynthesis/scale-up to support profiling studies
• Scaffold-hopping to identify new chemotypes

A constant communication with the customer's scientists (project management, chemists, biologists, toxicologists) insures the fast recognition of structure-activity relationships. Using parallel and/or convergent synthesis as well as traditional approaches, our scientists are able to synthesize quickly a significant variety of compounds.

Even in the early stages we design and synthesize compounds with improved pharmacokinetic (ADME) profiles: increased absorption, modified distribution, modulated sensitivity to metabolism and different elimination kinetics.

A robust, reproducible and a scaleable process is often the deciding factor for any biologically active molecule to advance as an API. Essentially, the process must be absolutely safe. Our experienced and specially trained scale-up group develop cost effective and safe processes by eliminating expensive and toxic reagents. We will try to avoid chromatography wherever possible and minimise waste. Solvents will be chosen with regard to their residual effects and for new APIs we ensure ICH guidelines are followed.

For pharmaceutical applications, manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates is conducted under current Good Manufacturing Practices (cGMP) at FDA approved facilities. SynInnova offers a broad range of cGMP manufacturing services to pharmaceutical and biotech companies worldwide. Our manufacturing partner in India has facilities meet global regulatory requirement.

Our reaction capabilities include: